Published: 15 September 2022
Author(s): Gregoire Stalder, William Reis Da Silva, Amandine Segot, Sabine Blum, Francesco Grandoni, Lorenzo Alberio
Issue: January 2023
Section: Letter to the Editor

Myeloproliferative neoplasms (MPN) are clonal diseases of hematopoietic stem cells characterized by the hyperplasia of one or more myeloid cell lines that retain their capacity for terminal differentiation [1]. Three entities that share overlapping but distinct clinical and laboratory characteristics are referred to as Philadelphia chromosome-negative (or BCR-ABL-negative) MPN: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The incidence of ET in Europe is estimated to be 0.4 to 1.7 per 100,000 person-years [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.